Anlotinib Alleviates Renal Fibrosis via Inhibition of the ERK and AKT Signaling Pathways
Oxidative Medicine and Cellular Longevity · 2023
DOI: 10.1155/2023/1686804 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oxidative Medicine and Cellular Longevity, 2023. Verfasst von Donglin Sun und 5 weiteren Autor:innen. Beteiligte Einrichtung: Guangzhou Medical University, Guangzhou 510000, China. Hauptthemen laut MEDLINE: Ureteral Obstruction, Kidney Diseases. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shenzhen Fundamental Research Program.
Abstract (Originalsprache)
Purpose
We examined whether anlotinib can attenuate folic acid-induced and unilateral ureteral obstruction-induced renal fibrosis and explored the underlying antifibrotic mechanism. Materials and Methods. We have evaluated the effects of anlotinib on folic acid-induced and unilateral ureteral obstruction-induced renal fibrosis in mice through in vivo experiments of unilateral ureteral obstruction or folic acid-induced interstitial fibrosis and in vitro models of transforming growth factor-β1 induced HK-2 human renal proximal tubule cells. Serum renal function parameters and inflammatory cytokine levels were measured, and histological changes of renal injury and fibrosis were analyzed by HE staining and immunohistochemistry. Immunohistochemistry and Western blotting were used to determine the mechanism of action of anlotinib in ameliorating renal fibrosis.
Results
Anlotinib improved proteinuria and reduced renal impairment in folic acid-induced mouse models of renal fibrosis. Anlotinib reduced tubular injury, deposition of tubular extracellular matrix, and expression of alpha-smooth muscle actin, transforming growth factor-β1, and cytosolic inflammatory factors compared with controls.
Conclusions
Anlotinib ameliorated renal function, improved extracellular matrix deposition, reduced protein levels of epithelial-mesenchymal transition markers, and decreased cellular inflammatory factors. Anlotinib reduced renal injury and fibrosis by inhibiting the transforming growth factor-β1 signaling pathway through AKT and ERK channels.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Guangzhou Medical University, Guangzhou 510000, China.
- Qingyuan People's Hospital, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan 511500, China.
- Department of Urology, Shenzhen Hospital, Southern Medical University, Shenzhen 518100, China.
- Southern Medical University Affiliated Longhua People's Hospital, Nephrology Department, Shenzhen, 518020 Guangdong, China.
ORCID-Profile: Donglin Sun, Jing Guo, Weifei Liang, Yangxiao Chen, Xiangqiu Chen, Li Wang
Förderung
- Shenzhen Fundamental Research Program
Zitieren
APA
Sun, D., Guo, J., Liang, W., Chen, Y., Chen, X., & Wang, L. (2023). Anlotinib Alleviates Renal Fibrosis via Inhibition of the ERK and AKT Signaling Pathways. Oxidative Medicine and Cellular Longevity. https://doi.org/10.1155/2023/1686804
Vancouver
Sun D, Guo J, Liang W, Chen Y, Chen X, Wang L. Anlotinib Alleviates Renal Fibrosis via Inhibition of the ERK and AKT Signaling Pathways. Oxidative Medicine and Cellular Longevity. 2023. doi:10.1155/2023/1686804
BibTeX
@article{Sun2023,
author = {Sun, Donglin and Guo, Jing and Liang, Weifei and Chen, Yangxiao and Chen, Xiangqiu and Wang, Li},
title = {Anlotinib Alleviates Renal Fibrosis via Inhibition of the ERK and AKT Signaling Pathways},
journal = {Oxidative Medicine and Cellular Longevity},
year = {2023},
doi = {10.1155/2023/1686804}
}
EUVIMED